Role of myeloid-derived suppressor cells in tumor immunotherapy.

Abstract:

:Myeloid-derived suppressor cells (MDSCs) are immature myeloid cells that infiltrate human and experimental tumors and strongly inhibit anticancer immune response directly or by inducing regulatory T-lymphocyte activity. Consequently, MDSCs are important actors of cancer-induced immune tolerance and a major obstacle to efficiency of cancer immunotherapy. Several means of preventing MDSCs accumulation or inhibiting their immunosuppressive effect were recently discovered in cancer-bearing hosts, contributing to restoring antitumor immunity and consequently to control of tumor growth. In experimental tumor models, targeting MDSCs can enhance the effects of active or passive immunotherapy. While similar effects have not yet been noted in cancer-bearing patients, recent preclinical findings demonstrating that the selective toxicity of conventional chemotherapies such as gemcitabine and 5-fluorouracil on MDSCs might contribute to their anticancer effect provide impetus to pursue investigations to unravel novel therapeutics that target MDSCs in humans.

journal_name

Immunotherapy

journal_title

Immunotherapy

authors

Martin F,Apetoh L,Ghiringhelli F

doi

10.2217/imt.11.154

subject

Has Abstract

pub_date

2012-01-01 00:00:00

pages

43-57

issue

1

eissn

1750-743X

issn

1750-7448

journal_volume

4

pub_type

杂志文章,评审
  • Essential role of CD4+ T cells for the activation of group 2 innate lymphoid cells during respiratory syncytial virus infection in mice.

    abstract::Aim: To investigate whether and how CD4+ T cells contribute to ILC2 activation during respiratory syncytial virus (RSV) infection. Methods: The methods of flow cytometry, quantitative PCR and ELISA were used in the present study. Results: Depletion of CD4+ T cells diminished the numbers of lung ILC2s as well as their ...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt-2019-0084

    authors: Han X,Bai S,Cui Y,Zhu W,Zhao N,Liu B

    更新日期:2019-10-01 00:00:00

  • Rate of cancer progression as a predictive marker of efficacy of immunotherapy; an analysis in metastatic non-small-cell lung cancer.

    abstract::Aim: To explore the value of rate of cancer progression (ROP) prior to starting PD-1 inhibitors as a predictive and prognostic biomarker. Materials & methods: Retrospective data of patients with metastatic non-small-cell lung cancer treated with second-line PD-1 inhibitors were collected. Patients were divided into tw...

    journal_title:Immunotherapy

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.2217/imt-2018-0180

    authors: Prasanna T,Arasaratnam M,Boyer M,McNeil C,Barnet MB,Asher R,Hui R,Nagrial A,Kao S

    更新日期:2019-06-01 00:00:00

  • Preventing stem cell transplantation-associated viral infections using T-cell therapy.

    abstract::Hematopoietic stem cell transplantation is the treatment of choice for many hematologic malignancies and genetic diseases. However, viral infections continue to account for substantial post-transplant morbidity and mortality. While antiviral drugs are available against some viruses, they are associated with significan...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.15.43

    authors: Tzannou I,Leen AM

    更新日期:2015-01-01 00:00:00

  • Adoptive therapy for EBV-induced cancers: driving success with post-transplant lymphoproliferative disorder to other EBV-derived tumors.

    abstract::Epstein-Barr virus (EBV) infection is associated with a range of human malignancies of lymphocytic and epithelial cell origin. In addition to viral-mediated and genetic oncogenic events that lead to the establishment of EBV-associated malignancies, defects in the immune control of EBV likely play a significant role in...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.15.7

    authors: Smith C,Khanna R

    更新日期:2015-01-01 00:00:00

  • The split personality of NKT cells in malignancy, autoimmune and allergic disorders.

    abstract::NKT cells are a heterogeneous subset of specialized, self-reactive T cells, with innate and adaptive immune properties, which allow them to bridge innate and adaptive immunity and profoundly influence autoimmune and malignant disease outcomes. NKT cells mediate these activities through their ability to rapidly express...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.11.117

    authors: Subleski JJ,Jiang Q,Weiss JM,Wiltrout RH

    更新日期:2011-10-01 00:00:00

  • A case of fulminant Type 1 diabetes following anti-PD1 immunotherapy in a genetically susceptible patient.

    abstract::Programmed cell death-1 protein (PD-1) is an immune checkpoint that has gained popularity in the treatment of several advanced cancers. Inhibiting this checkpoint is known to enhance immune response, but is also known to diminish immune tolerance and to increase autoimmune toxicity. We discuss a case of rapid onset fu...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt-2017-0020

    authors: Araújo M,Ligeiro D,Costa L,Marques F,Trindade H,Correia JM,Fonseca C

    更新日期:2017-06-01 00:00:00

  • mRNA: delivering an antitumor message?

    abstract::Evaluation of: Fotin-Mleczek M, Duchardt KM, Lorenz C et al.: Messenger RNA-based vaccines with dual activity induce balanced TLR7-dependent adaptive immune responses and provide antitumor activity. J. Immunother. 34(1), 1-15 (2011). Two decades ago, mRNA was proposed as an active pharmaceutical ingredient for the the...

    journal_title:Immunotherapy

    pub_type: 评论,杂志文章

    doi:10.2217/imt.11.28

    authors: Van Lint S,Thielemans K,Breckpot K

    更新日期:2011-05-01 00:00:00

  • Timely blockade of ICAM-1.LFA-1 interaction prevents disease onset in a mouse model of emphysema.

    abstract:AIM:It is becoming apparent that emphysema is partly driven by self-reactive T cells inducing inflammatory damage. Thus, T cells become targets for therapy similar to other autoimmune diseases. Costimulatory blockade therapy targets disease-specific T cells, rendering them ineffective by blocking a necessary costimulat...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt.15.31

    authors: Newton AH,Danahy DB,Chan MA,Benedict SH

    更新日期:2015-01-01 00:00:00

  • Updates and new perspectives in nonmelanoma skin cancer therapy: highlights from 'Immunotherapy Bridge'.

    abstract::Over the last few years, extensive research has improved our understanding of tumor immunology and has enabled the development of novel treatments. The state of the art of immunotherapy in various types of malignancies was exhaustively discussed in the 'Immunotherapy Bridge' meeting, which was held in Naples on 4-5 De...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt-2020-0042

    authors: Ascierto PA,Garbe C

    更新日期:2020-02-01 00:00:00

  • Intestinal microbiota predicts lung cancer patients at risk of immune-related diarrhea.

    abstract:AIM:Previous studies showed that some patients after the treatment of anti-programmed cell death protein-1 (anti-PD-1) antibodies experienced immune-related diarrhea. In this study, we aim to explore the association between intestinal microbiota and immune-related diarrhea. METHODS:We obtained the fecal samples of 26 ...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt-2018-0144

    authors: Liu T,Xiong Q,Li L,Hu Y

    更新日期:2019-04-01 00:00:00

  • Vaccinia virus, a promising new therapeutic agent for pancreatic cancer.

    abstract::The poor prognosis of pancreatic cancer patients signifies a need for radically new therapeutic strategies. Tumor-targeted oncolytic viruses have emerged as attractive therapeutic candidates for cancer treatment due to their inherent ability to specifically target and lyse tumor cells as well as induce antitumor effec...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.15.90

    authors: Al Yaghchi C,Zhang Z,Alusi G,Lemoine NR,Wang Y

    更新日期:2015-01-01 00:00:00

  • Immunotherapy of chronic myeloid leukemia: present state and future prospects.

    abstract::In spite of the considerable successes that have been achieved in the treatment of chronic myeloid leukemia (CML), cure for the disease can only be obtained by the present means in a rather small minority of patients. During the past decade, considerable progress has been made in the understanding of the immunology of...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.10.2

    authors: Vonka V

    更新日期:2010-03-01 00:00:00

  • Immune adjuvants in early life: targeting the innate immune system to overcome impaired adaptive response.

    abstract::The neonatal phase is a transitory period characterized by an absence of memory cells, favoring a slow adaptive response prone to tolerance effects and the development of Th2-type responses. However, when appropriately stimulated, neonates may achieve an immune response comparable with adult counterparts. One strategy...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.09.38

    authors: de Brito CA,Goldoni AL,Sato MN

    更新日期:2009-09-01 00:00:00

  • Kinoids: a family of immunogens for active anticytokine immunotherapy applied to autoimmune diseases and cancer.

    abstract::The complex homeostasis of tissues is coordinated by the cytokine network and imbalances in this network may result in chronic immune disorders. Key specific cytokines, such as TNF-alpha, IFN-alpha, IL-4 or VEGF have been demonstrated to be overproduced or abnormally released in the microenvironment of pathologic tiss...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.10.16

    authors: Bizzini B,Drouet B,Zagury D,Abitbol M,Burny A,Boissier MC

    更新日期:2010-05-01 00:00:00

  • Bacillus Calmette-Guerin immunotherapy for urothelial carcinoma of the bladder.

    abstract::Mycobacterium bovis bacille Calmette-Guerin (BCG) is one of the great success stories of immunotherapy as a treatment for superficial urothelial carcinoma of the bladder. Despite clinical effectiveness in over 50% of patients, the high incidence of local side effects and presence of nonresponders has led to efforts to...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/1750743X.1.2.281

    authors: Kresowik TP,Griffith TS

    更新日期:2009-03-01 00:00:00

  • FOCIS goes south: advances in translational and clinical immunology.

    abstract::FOCIS goes South: Advances in Translational and Clinical Immunology was the first Federation of Clinical Immunology Societies (FOCIS) ( www.focisnet.org ) meeting held in Latin America (May 15-17, 2017, Santiago de Chile, Chile). The meeting was organized as a 3-day workshop and was fostered by the Millennium Institut...

    journal_title:Immunotherapy

    pub_type:

    doi:10.2217/imt-2017-0079

    authors: Kalergis AM,Anegon I,González PA

    更新日期:2017-09-01 00:00:00

  • Anti-TNF therapeutics for the treatment of sarcoidosis.

    abstract::Sarcoidosis is a systemic disease with an incidence of 1 to 40 per 100 000 persons per year. It predominantly affects people in the age of 20 to 40 years old. Disease course varies from mild self-limiting to chronic debilitating and life-threatening disease. Since the cause of sarcoidosis is unknown, curative therapy ...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.14.65

    authors: Crommelin HA,Vorselaars AD,van Moorsel CH,Korenromp IH,Deneer VH,Grutters JC

    更新日期:2014-01-01 00:00:00

  • Cancer testis antigens as immunogenic and oncogenic targets in breast cancer.

    abstract::Breast cancer cells frequently express tumor-associated antigens that can elicit immune responses to eradicate cancer. Cancer-testis antigens (CTAs) are a group of tumor-associated antigens that might serve as ideal targets for cancer immunotherapy because of their cancer-restricted expression and robust immunogenicit...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt-2017-0179

    authors: Mahmoud AM

    更新日期:2018-07-01 00:00:00

  • Fibroblastic reticular cell infection by hemorrhagic fever viruses.

    abstract::Viral hemorrhagic fevers (VHFs) often cause high mortality with high infectivity, multiorgan failure, shock and hemorrhagic diathesis. Fibroblastic reticular cells (FRCs) within secondary lymphoid organs provide a supporting scaffold to T-lymphocyte areas. These cells regulate the movement of various immune cells and ...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/1750743X.1.2.187

    authors: Steele KE,Anderson AO,Mohamadzadeh M

    更新日期:2009-03-01 00:00:00

  • Antibody-targeted nanoparticles for cancer therapy.

    abstract::In recent years, nanoparticulate-mediated drug delivery research has examined a full spectrum of nanoparticles that can be used in diagnostic and therapeutic cancer applications. A key aspect of this technology is in the potential to specifically target the nanoparticles to diseased cells using a range of molecules, i...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.11.5

    authors: Fay F,Scott CJ

    更新日期:2011-03-01 00:00:00

  • Cancer-testis genes as candidates for immunotherapy in breast cancer.

    abstract::Cancer-testis (CT) antigens are tumor-associated antigens attracting immunologists for their possible application in the immunotherapy of cancer. Several clinical trials have assessed their therapeutic potentials in cancer patients. Breast cancers, especially triple-negative cancers are among those with significant ex...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.13.165

    authors: Ghafouri-Fard S,Shamsi R,Seifi-Alan M,Javaheri M,Tabarestani S

    更新日期:2014-01-01 00:00:00

  • Interview: Investigating immunomodulators among the Actinomycetales. Interview by Hannah Wilson.

    abstract::John L Stanford speaks to Hannah Wilson, Assistant Commissioning Editor John L Stanford is Chief Scientific Officer at BioEos Ltd (Kent, UK). Dr Stanford began his career as a senior lecturer and then reader in microbiology at Middlesex Hospital Medical School (London, UK), then University College London Medical Schoo...

    journal_title:Immunotherapy

    pub_type: 面试,新闻

    doi:10.2217/imt.13.27

    authors: Stanford JL

    更新日期:2013-05-01 00:00:00

  • Heat-shock proteins as endogenous ligands building a bridge between innate and adaptive immunity.

    abstract::There has been growing evidence that heat-shock protein (HSP) functions as an endogenous immunomodulator for innate and adaptive immune responses. Since HSPs inherently act as chaperones within cells, passive release (e.g., by cell necrosis) and active release (including release by secretion in the form of an exosome)...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.12.75

    authors: Tamura Y,Torigoe T,Kukita K,Saito K,Okuya K,Kutomi G,Hirata K,Sato N

    更新日期:2012-08-01 00:00:00

  • MAGE-A3: an immunogenic target used in clinical practice.

    abstract::Melanoma antigen family A, 3 (MAGE-A3) is a cancer-testis antigen whose expression has been demonstrated in a wide array of malignancies including melanoma, brain, breast, lung and ovarian cancer. In addition, its ability to elicit spontaneous humoral and cellular immune responses has been shown in cancer patients. As...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.15.29

    authors: Esfandiary A,Ghafouri-Fard S

    更新日期:2015-01-01 00:00:00

  • Designing effective vaccines for colorectal cancer.

    abstract::Achieving long-term control of colorectal cancers with therapeutic vaccines that generate potent anti-tumor T cell and antibody responses has been a goal for more than two decades. To date, clinical trials of these vaccines have demonstrated induction of immune responses, but clinical benefit has been limited. Improve...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.14.61

    authors: Patel SP,Osada T,Lyerly HK,Morse MA

    更新日期:2014-01-01 00:00:00

  • New immunotherapeutic strategies for the treatment of neuroblastoma.

    abstract::The prognosis of high-risk neuroblastoma (NB) is still poor, in spite of aggressive multimodal treatment. Recently, adjuvant immunotherapy with anti-GD2 antibodies combined with IL-2 or GM-CSF has been shown to improve survival. Several other immunotherapy strategies proved efficacy in preclinical models of NB, includ...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.14.117

    authors: Croce M,Corrias MV,Rigo V,Ferrini S

    更新日期:2015-01-01 00:00:00

  • What is the role of antigen-processing mechanisms in autologous tolerogenic dendritic cell therapy in organ transplantation?

    abstract::Injection of autologous tolerogenic dendritic cells is a promising strategy to diminish the burden of harmful immunosuppression in clinical transplantation. We discuss the immunoregulatory mechanisms triggered by this approach. Tolerogenic dendritic cells have long been associated with decreased antigen-processing cap...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.11.40

    authors: Hill M,Segovia M,Cuturi MC

    更新日期:2011-04-01 00:00:00

  • Dendritic cell vaccines targeting survivin in head and neck cancer.

    abstract::Evaluation of: Turksma AW, Bontkes HJ, Ruizendaal JJ et al. Exploring dendritic cell based vaccines targeting survivin for the treatment of head and neck cancer patients. J. Transl. Med. 11, 152-165 (2013). Survivin has been identified to be an inhibitor of apoptosis and is highly expressed in many cancers. A number o...

    journal_title:Immunotherapy

    pub_type: 评论,杂志文章

    doi:10.2217/imt.13.120

    authors: Lee WT

    更新日期:2013-11-01 00:00:00

  • Restricted mean survival time as outcome measure in advanced urothelial bladder cancer: analysis of 4 clinical studies.

    abstract::Background: The purpose of this study was to assess the effectiveness of immune checkpoint inhibitors (ICIs) in advanced urothelial carcinoma. Materials & methods: We selected seven cohorts of patients published in four clinical trials. The restricted mean survival time (RMST) was used to analyze survival curves, perf...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt-2020-0160

    authors: Rivano M,Cancanelli L,Spazio LD,Chiumente M,Mengato D,Messori A

    更新日期:2021-02-01 00:00:00

  • Tumor lysate particle loaded dendritic cell vaccine: preclinical testing of a novel personalized cancer vaccine.

    abstract:AIM:We developed a novel approach to efficiently deliver autologous tumor antigens to the cytoplasm of dendritic cells (DC) using yeast cell wall particles (YCWP). MATERIALS AND METHODS:Loading of YCWP, leakage of protein from loaded YCWP and cytoplasmic delivery of YCWP content was assessed using fluorescent-tagged e...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt-2017-0114

    authors: Hardin MO,Vreeland TJ,Clifton GT,Hale DF,Herbert GS,Greene JM,Jackson DO,Berry JE,Nichols P,Yin S,Yu X,Wagner TE,Peoples GE

    更新日期:2018-04-01 00:00:00